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1
L O W  L U N G  C A N C E R  S C R E E N I N G  R A T E S
• 2021 USPSTF Lung Cancer Screening Guidelines: 
• Annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years 
who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years.1
• Screening should be discontinued once a person has not smoked for 15 years or develops a health problem 
that substantially limits life expectancy or the ability or willingness to have curative lung surgery.1
• National LDCT lung cancer screening rate for eligible patients in 2018 roughly 5.0%2
• Uptake varies regionally; 13.8% of eligible Vermonters screened, 2nd highest nationally3
• 2016 VT breast cancer screening rate: 79%4
• 2016 VT colorectal cancer screening rate: 72%4
• Breakdown in EMR trigger for lung cancer screening likely 1 cause of care gap
• Epic EMR only allows for 1 set of start and stop smoking dates & 1 option for PPD
• For many smokers this does not allow for an accurate capture of their smoking history
• This leads to patients who do meet screening criteria being missed because the EMR does not trigger LDCT 
screening reminder through the Health Maintenance Tab
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C O S T  O F  L U N G  C A N C E R
• 79% of patients present with regional lymph node involvement or distant metastases, compared to 17% who present 
with only local disease1
• Patients with localized disease have a 59% 5-year survival rate, compared with 32% for those with regional spread, and 
6% for those with distant metastases1
• Estimated 235,760 new lung cancers and 131,880 lung cancer deaths in 20215
• Average lung cancer treatment costs in 2017:
• Cost per month during the pre-diagnosis phase was $861. For patients who did not receive surgery, costs during the month of 
staging range from $6,670 to $13,6086
• For a patient who received surgery, average costs during the month beginning on the date of surgery were $30,0966
• Surgical intervention often more affordable than chemotherapy and/or radiation6
• Vermont was one of the 38 states whose Medicaid fee-for-service programs covered lung cancer screening as of February 
20204
3
C O M M U N I T Y  P E R S P E C T I V E
“We all know to do lung cancer screening, but 
I didn’t know that guidelines had been 
updated. Our EMR doesn’t trigger reminders 
for everyone [who meet criteria] or track it 
correctly” 
- Katherine Mariani, MD 
South Burlington Family Practice Physician 
“Patients are very open to lung cancer 
screening; they know that they are at risk for 
lung cancer if they smoke. The LDCT for 
screening appeals to most as it is well 
tolerated, quick, and affordable. Getting 
screens annually is more challenging” 
- Clara Keegan, MD
South Burlington Family Practice Physician 
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I N T E R V E N T I O N
• 3 SmartPhrases were created in Epic to aid in increasing LDCT lung cancer screening rates 
• Checking if patient meets 2021 criteria: “.LCSCREEN”
• Counseling statement: “.LDCTCOUNSEL”
• After visit summary information on LDCT screening: “.LUNGCANCERSCREENING21UPDATE”
• SmartPhrase Summary document distributed to all providers in the department
To access these SmartPhrases in UVMMC Epic, go to SmartPhrases > Manage Phrases > Search 
User > Schimmel, McKenna >  LCSCREEN or LDCTCOUNSEL or LUNGCANCERSCREENING21UPDATE
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R E S P O N S E
• South Burlington Family Practice Providers were supportive of improving the process 
for identifying which patients on their panel meet current USPSTF lung cancer 
screening guidelines
• Providers appreciated having multiple options for integration that they could 
personalize to their note preferences 
• Several providers were not aware that guidelines had been updated 
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E F F E C T I V E N E S S  O F  I N T E R V E N T I O N  
P R O P O S E D  E V A L U AT I O N  
• Follow up survey assessing ease of use
• Track impact on department-wide 
screening rates 
L I M I TAT I O N S
• The information was not conveyed to other 
types of providers, such as nurses, or 
support staff at the clinic. 
• Short duration of the rotation limited 
potential of changes to the EMR
• Intervention was focused on providers and 
not patient perspective 
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R E C O M M E N D A T I O N S  
• Vermont has the potential to lead the nation in appropriate lung cancer screening 
rates 
• All providers should be aware of the updated 2021 USPSTF Lung Cancer Screening 
Guidelines and implementing them in their practice
• Making identification of patients who meet screening guidelines more efficient will 
help us to get screening to those who qualify and keep Vermonters healthy 
• In the future, an Epic update allowing for multiple periods of smoking to be tracked 
would be immensely beneficial 
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